Lee Ainslie Adagio Therapeutics, Inc. Transaction History
Maverick Capital LTD
- $5.08 Billion
- Q1 2025
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Maverick Capital LTD holds 10,958,572 shares of ADGI stock, worth $36.3 Million. This represents 0.71% of its overall portfolio holdings.
Number of Shares
10,958,572
Previous 11,765,787
6.86%
Holding current value
$36.3 Million
Previous $38.9 Million
6.86%
% of portfolio
0.71%
Previous 0.75%
Shares
6 transactions
Others Institutions Holding ADGI
# of Institutions
74Shares Held
65.4MCall Options Held
31.6KPut Options Held
54.3K-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million27.49% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.72MShares$32.2 Million1.13% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million32.33% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.93MShares$13 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...